Cohance Lifesciences Ltd

Cohance Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Cohance Lifesciences Ltd

₹ 629 -8.81%
13 Nov - close price
cohance.com BSE: 543064 NSE: COHANCE
About

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]

Key Points

Market Position
The company has established a strong presence in the contract research and manufacturing services (CRAMS) sector and is one of the top 5 providers of high-end intermediates to innovators in India. [1]

Website BSE NSE
  • Market Cap ₹ 24,080 Cr.
  • Current Price ₹ 629
  • High / Low ₹ 1,360 / 621
  • Stock P/E 64.9
  • Book Value ₹ 115
  • Dividend Yield 0.00 %
  • ROCE 16.0 %
  • ROE 12.5 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -8.92%
  • The company has delivered a poor sales growth of 5.57% over past five years.
  • Promoters have pledged or encumbered 100% of their holding.
  • Debtor days have increased from 52.5 to 80.9 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty MNC

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
278 348 364 344 225 213 253 488 594 284 769 484 498
172 201 187 174 127 144 180 363 391 171 546 379 367
Operating Profit 107 147 177 170 97 69 73 125 204 113 223 104 131
OPM % 38% 42% 49% 49% 43% 32% 29% 26% 34% 40% 29% 22% 26%
10 13 11 10 14 14 17 19 16 16 -8 5 26
Interest 0 1 5 1 0 2 2 10 9 3 7 7 5
Depreciation 11 11 11 11 10 11 17 31 35 15 43 31 31
Profit before tax 106 147 172 168 101 70 71 103 175 111 166 71 121
Tax % 26% 26% 25% 26% 26% 25% 25% 27% 21% 25% 26% 26% 22%
79 109 130 124 75 52 53 75 139 84 123 53 94
EPS in Rs 3.10 4.30 5.11 4.88 2.94 2.06 2.09 2.96 5.46 3.29 4.82 1.37 2.46
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 5m Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
378 834 1,010 1,320 1,330 1,051 1,094 2,034
206 449 567 738 739 645 731 1,463
Operating Profit 172 385 443 582 591 406 363 571
OPM % 45% 46% 44% 44% 44% 39% 33% 28%
1 18 14 188 45 57 54 39
Interest 3 22 12 9 13 7 8 22
Depreciation 12 24 32 39 43 55 57 120
Profit before tax 158 358 414 722 579 400 351 469
Tax % 31% 24% 25% 23% 25% 26% 23%
109 270 309 558 433 296 272 353
EPS in Rs 10.61 12.12 21.92 16.99 11.65 10.67 11.94
Dividend Payout % 0% 24% 16% 23% 35% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 6%
3 Years: -6%
TTM: 31%
Compounded Profit Growth
10 Years: %
5 Years: 0%
3 Years: -21%
TTM: 16%
Stock Price CAGR
10 Years: %
5 Years: 14%
3 Years: 13%
1 Year: -50%
Return on Equity
10 Years: %
5 Years: 23%
3 Years: 17%
Last Year: 13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 0.00 13 25 25 25 25 25 38
Reserves 578 770 1,040 1,495 1,724 2,003 2,290 4,371
83 186 143 97 70 65 99 240
123 142 151 187 139 121 174 447
Total Liabilities 783 1,111 1,359 1,805 1,958 2,214 2,588 5,096
271 357 441 534 512 670 685 2,083
CWIP 111 102 96 30 165 179 254 335
Investments 7 276 426 600 710 893 1,116 1,224
394 376 395 641 571 473 533 1,455
Total Assets 783 1,111 1,359 1,805 1,958 2,214 2,588 5,096

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
50 359 330 270 493 376 301
-65 -367 -258 -90 -237 -362 -321
26 9 -77 -156 -243 -40 21
Net Cash Flow 11 1 -4 23 13 -26 1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 142 51 37 65 30 46 81
Inventory Days 556 278 243 259 284 268 188
Days Payable 190 113 100 97 61 49 87
Cash Conversion Cycle 509 217 180 228 253 265 182
Working Capital Days 205 64 56 107 99 108 94
ROCE % 46% 39% 50% 34% 21% 16%

Shareholding Pattern

Numbers in percentages

8 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
60.00% 60.00% 60.00% 60.00% 60.00% 50.10% 50.10% 50.10% 50.10% 50.10% 66.41% 57.49%
8.11% 9.47% 9.50% 10.01% 10.14% 9.54% 9.80% 10.70% 10.84% 11.05% 7.23% 6.51%
11.36% 11.43% 10.63% 14.13% 15.94% 17.24% 17.42% 16.95% 16.67% 16.60% 11.40% 20.81%
0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
20.55% 19.10% 19.88% 15.85% 13.93% 23.11% 22.67% 22.26% 22.37% 22.24% 14.95% 15.16%
No. of Shareholders 79,41272,88572,16773,71570,05268,93265,77769,33784,21086,32580,91075,284

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls